ライフサイエンスコーパス: oesophageal cancer

1 , ongoing controversies, and future needs in oesophageal cancer.

2 ry as standard treatment of locally advanced oesophageal cancer.

3 ompared with surgery alone for patients with oesophageal cancer.

4 tasis precludes long-term survival in distal oesophageal cancer.

5 lignant dysphagia in patients with incurable oesophageal cancer.

6 sociation was seen with risk or survival for oesophageal cancer.

7 dence for surgery in the treatment of gastro-oesophageal cancer.

8 with placebo in previously treated advanced oesophageal cancer.

9 the development of Barrett's metaplasia and oesophageal cancer.

10 SEMS effectively palliate inoperable oesophageal cancer.

11 n is the mainstay of treatment for localised oesophageal cancer.

12 d epigenetically or in regulatory regions in oesophageal cancer.

13 tify a gene that may be involved in familial oesophageal cancer.

14 ocally advanced resectable gastric or gastro-oesophageal cancer.

15 bition has shown efficacy in advanced gastro-oesophageal cancer.

16 bleeding after radical treatment for gastro-oesophageal cancer.

17 erapy response prediction in lung and gastro-oesophageal cancers.

18 osinophilic oesophagitis (EoE), stenosis, or oesophageal cancer (1).

19 ly pre-treated patients with advanced gastro-oesophageal cancer(12).

20 for ovarian cancer, 34.9 to 59.8 (47.2%) for oesophageal cancer, 22.3 to 62.3 (40.8%) for rectal canc

21 itional deaths, a 4.8-5.3% increase; and for oesophageal cancer, 330 (324-335) to 342 (336-348) addit

22 Is: 17.8 to 82.4 (pooled estimate 50.2%) for oesophageal cancer, 35.5 to 55.2 (45.2%) for rectal canc

23 ared with April, 2019, increased by 41.2% in oesophageal cancer, 64.2% in bladder cancer, and 36.3% i

24 The odds of being a case of oesophageal cancer, adjusted for smoking status, were si

25 n neoadjuvant therapies for locally advanced oesophageal cancer and immune checkpoint inhibitor-based

26 py alone as first-line treatment in advanced oesophageal cancer and Siewert type 1 gastro-oesophageal

27 er, 24 975 with colorectal cancer, 6744 with oesophageal cancer, and 29 305 with lung cancer.

28 t of early gastrointestinal cancers, such as oesophageal cancer, and lung cancer.

29 nut are known risk factors for many oral and oesophageal cancers, and their use is highly prevalent i

30 with or using other agents targeting HER2 in oesophageal cancer are warranted.

31 S are placed in all patients with inoperable oesophageal cancer, as in our study, rather than those f

32 he absence of early diagnosis contributes to oesophageal cancer being the sixth most common cause of

33 For lung and oesophageal cancer, benefit was confined to adenocarcino

34 ears, diagnosed with breast, colorectal, and oesophageal cancer between Jan 1, 2010, and Dec 31, 2010

35 Long-term complications can, rarely, include oesophageal cancer, but surveillance recommendations hav

36 ixed, wax-embedded sections from a series of oesophageal cancer cases previously shown to contain MMP

37 rative effects in colonic mucosa and in some oesophageal cancer cell lines.

38 data from 150 BE and 285 EAC cases from the Oesophageal Cancer Classification and Molecular Stratifi

39 identified from the prospective national UK Oesophageal Cancer Clinical and Molecular Stratification

40 ticipants were registered (115 in the gastro-oesophageal cancer cohort, 950 in the colorectal cancer

41 ntestinal bleeding (any grade) in the gastro-oesophageal cancer cohort.

42 Endoscopic detection of oesophageal cancer (EC) often occurs late in disease dev

43 circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients undergoing concurrent c

44 the recently published chemoradiotherapy for oesophageal cancer followed by surgery study trial showe

45 isease locus [previously termed the "tylosis oesophageal cancer gene' (TOC) locus] has been mapped to

46 of individuals who have an elevated risk of oesophageal cancer has changed dramatically.

47 The prognosis of oesophageal cancer has greatly improved due to breakthro

48 ncer, colorectal cancer, endometrial cancer, oesophageal cancer, head and neck cancer, ovarian cancer

49 urgical resection for stage III or IV distal oesophageal cancer in 1987-2010 with follow-up until 201

50 EMS placement as sole therapy for inoperable oesophageal cancer in a resource-limited setting.

51 ce for an increase in the risk of gastric or oesophageal cancer in bisphosphonate users and one findi

52 an appropriate technology for palliation of oesophageal cancer in resource-limited settings.

53 ost all patients who underwent resection for oesophageal cancer in Sweden in 1987-2010.

54 ermal dysplasia type III) is associated with oesophageal cancer in three families: two large pedigree

55 e of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not impro

56 rt a small but significant increased risk of oesophageal cancer in women prescribed bisphosphonates a

57 Therapies for inoperable oesophageal cancer include chemoradiotherapy and placeme

58 Endoscopically diagnosed oesophageal cancer increased by 32 % per decade, but gas

59 Oesophageal cancer is a clinically challenging disease t

60 First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimid

61 Oesophageal cancer is one of the 10 leading causes of ca

62 and radiotherapy, to treat locally advanced oesophageal cancer is particularly notable.

63 c role of lymphadenectomy during surgery for oesophageal cancer is questioned.

64 and overall survival in HER2-positive gastro-oesophageal cancer is scarce.

65 ed advance in the treatment of patients with oesophageal cancer is the advent of immune-checkpoint in

66 Oesophageal cancer is the seventh leading cause of cance

67 a small but significantly increased risk of oesophageal cancer linked to duration of bisphosphonate

68 surgical removal of primary lung, breast and oesophageal cancers, low-dose adjuvant epigenetic therap

69 of Life Questionnaire-Core 30 (QLQ-C30) and -Oesophageal Cancer Module (QLQ-OES24) questionnaires pre

70 cancer (GC) cases was 658 (3%) while that of oesophageal cancer (OC) was 1168 (5%).

71 ccepted as a standard tool in the staging of oesophageal cancer (OC).

72 The care of patients with oesophageal cancer or of individuals who have an elevate

73 locally advanced, unresectable or metastatic oesophageal cancer or Siewert type 1 gastro-oesophageal

74 eligible patients were adults with advanced oesophageal cancer or type I/II Siewert junctional tumou

75 odeoxyglucose ((18)F-FDG) PET images for 441 oesophageal cancer patients (split: testing = 353, valid

76 er cardiovascular and circulatory disorders, oesophageal cancer, preterm birth complications, congeni

77 carce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and n

78 cuss all these advances in the management of oesophageal cancer, representing only the beginning of a

79 the promoter is hypermethylated in sporadic oesophageal cancer samples: this may constitute the 'sec

80 ciated with the early onset of squamous cell oesophageal cancer (SCOC) in three families.

81 otherapy for metastatic HER2-positive gastro-oesophageal cancer, specifically in patients with tumour

82 rapy cannot be recommended for patients with oesophageal cancer suitable for definitive CRT.

83 Lymphadenectomy during oesophageal cancer surgery is a safe procedure in the sh

84 are the cause of the inherited cutaneous and oesophageal cancer-susceptibility syndrome tylosis with

85 Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative trea

86 For oral, oropharyngeal and oesophageal cancer, the early detection of tumours and o

87 e has the potential to improve screening for oesophageal cancers through the development of novel min

88 ls in a collection of DNA samples taken from oesophageal cancer tissues.

89 erma (Tylosis) associated with squamous cell oesophageal cancer (TOC) has been mapped to chromosome 1

90 lotype analyses have mapped the tylosis with oesophageal cancer (TOC) locus to a 42.5 kb region on ch

91 ned entirely within the 42.5 kb tylosis with oesophageal cancer (TOC) minimal region.

92 ies of patients with psoriasis, tylosis with oesophageal cancer (TOC), and non-epidermolytic palmopla

93 on mutations in iRHOM2 underlie Tylosis with oesophageal cancer (TOC), characterized by palmoplantar

94 cancer-susceptibility syndrome tylosis with oesophageal cancer (TOC), suggesting a role for this pro

95 amplified cancers excluding breast or gastro-oesophageal cancers; total n=86) was 20 mg/kg every 2 we

96 prospectively gathered on all patients with oesophageal cancer treated with SEMS between Jan 1, 1999

97 nt chemoradiotherapy for HER2-overexpressing oesophageal cancer was not effective.

98 s ovarian cancer, uterine tumours and gastro-oesophageal cancers, where high cyclin E levels are asso

99 ncluded patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) thro

100 Thus, patients with distal oesophageal cancer with coeliac node metastasis seem to

101 notherapy has become a crucial treatment for oesophageal cancer, with immune checkpoint inhibitor-bas